Open Access

Platelet‑to‑lymphocyte and neutrophil‑to‑lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non‑small cell lung cancer

  • Authors:
    • Xiaojuan Lu
    • Junyan Wan
    • Huaqiu Shi
  • View Affiliations

  • Published online on: June 17, 2022     https://doi.org/10.3892/ol.2022.13386
  • Article Number: 266
  • Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Peripheral serological indicators are novel markers associated with prognosis in multiple malignant tumors. In the present study, platelet‑to‑lymphocyte ratio (PLR) and neutrophil‑to‑lymphocyte ratio (NLR) were selected to construct a model that predicts long‑term survival of patients with stage IIIB‑IV non‑small cell lung cancer (NSCLC) who received treatment with an anti‑programmed cell death protein‑1 (PD‑1) monoclonal antibody. A total of 133 patients were eligible for the present retrospective study (January 2019‑February 2021). The area under the receiver operating characteristic curve was used to compare the diagnostic value of PLR and NLR, and combined PLR and NLR. The objective response rate and disease control rate of each group were obtained and the differences were compared using the χ2 test. The prognostic value of these indicators was assessed using the Kaplan‑Meier method. Cox regression analysis was used to evaluate risk factors associated with long‑term survival. Statistically significant parameters were included in the nomogram. Based on the median PLR and NLR values, the patients were divided into high PLR (H‑PLR) (PLR >200.00, 67 patients) and low PLR (L‑PLR) (PLR ≤200.00, 66 patients), and high NLR (H‑NLR) (NLR >3.56, 65 patients) and low NLR (L‑NLR) (NLR ≤3.56, 68 patients) groups. Immune‑related adverse events (irAEs) occurred in 22 patients (16.5%) during the observation period, including 18 grade 2‑3 irAEs and 4 grade 4 cases. H‑NLR and H‑PLR were associated with poor progression‑free (PFS) and overall survival (OS) in the present study. NLR was an independent prognostic factor for PFS [hazard ratio (HR): 0.201, 95% confidence interval (CI): 0.060‑0.670; P=0.009) and OS (HR: 0.413, 95% CI: 0.226‑0.754; P=0.004) in this patient group. Therefore, NLR may be used in the prognostication of patients with stage IIIB‑IV NSCLC treated with PD‑1 inhibitors. These serological markers may be used in combination with established immunomarkers to help predict outcomes.
View Figures
View References

Related Articles

Journal Cover

August-2022
Volume 24 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lu X, Wan J and Shi H: Platelet‑to‑lymphocyte and neutrophil‑to‑lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non‑small cell lung cancer. Oncol Lett 24: 266, 2022
APA
Lu, X., Wan, J., & Shi, H. (2022). Platelet‑to‑lymphocyte and neutrophil‑to‑lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non‑small cell lung cancer. Oncology Letters, 24, 266. https://doi.org/10.3892/ol.2022.13386
MLA
Lu, X., Wan, J., Shi, H."Platelet‑to‑lymphocyte and neutrophil‑to‑lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non‑small cell lung cancer". Oncology Letters 24.2 (2022): 266.
Chicago
Lu, X., Wan, J., Shi, H."Platelet‑to‑lymphocyte and neutrophil‑to‑lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non‑small cell lung cancer". Oncology Letters 24, no. 2 (2022): 266. https://doi.org/10.3892/ol.2022.13386